Mukthinuthalapati Mathrusri Annapurna* and Pinninti Pradeep
Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India
*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.
Received: October 18, 2024; Published: October 28, 2024
Citation: Mukthinuthalapati Mathrusri Annapurna and Pinninti Pradeep. “Analytical Methods for the Estimation of Relugolix – A Review". Acta Scientific Pharmaceutical Sciences 8.11 (2024):39-40.
Relugolix is used to treat advanced prostate cancer in men. Relugolix is used in the treatment of advanced hormone sensitive prostate cancer and also to manage heavy menstrual bleeding and severe pain. In the present study the authors have reviewed and summarised the analytical methods so far developed for the estimation of Relugolix in pharmaceutical formulations as well as biological fluids.
Keywords: Relugolix; Pain
Relugolix (CAS: 737789-87-6) is chemically 1- [4- [1-[(2,6-difluoro phenyl) methyl]-5-[(dimethyl amino) methyl]-3-(6-methoxy pyridazin-3-yl)-2,4-dioxothieno[2,3-d] pyrimidin-6-yl] phenyl]-3-methoxy urea with molecular weight 623.6 g/mol. Relugolix is used in the treatment of advanced hormone sensitive prostate cancer [1] and also to manage heavy menstrual bleeding and severe pain [2-4]. Relugolix is soluble in organic solvents such as Ethanol, DMSO and dimethyl formamide and the solubility in these solvents is approximately 1, 20 and 25 mg/ml respectively and the pKa value is 8.63. Relugolix is a competitive antagonist of Gonadotropin-releasing hormone receptors, thereby decreasing the release of Luteinizing hormone and ultimately Testosterone. Relugolix is available as tablets with label claim 120 mg with brand names Rexigo (Zydus Cadila), R-Golix (Ipca Laboratories Ltd), OrgOnist (Sun Pharmaceuticals), Xelucip (Cipla Ltd) in India. The analytical methods such as UPLC-MS/MS [5], UPLC-MS [6], LC-MS/MS [7] RP-UPLC [8] RP-HPLC [9,10] were developed for the estimation of Relugolix and its impurities were studied by different authors in pharmaceutical dosage forms as well as biological fluids and some of the parameters were discussed in detail in Table 1.
Figure 1: Chemical structure of Relugolix (C29H27F2N7O5S).
Tucatinib is available as tablets with brand names Tucaxen 150 (Everest) Tukysa (Seetle Genetics), TukadxTM (Bigbear Pharmaceutical Laos) etc and label claim 150 mg. The analytical methods such as LC-MS/MS [4], UPLC-MS/MS [5], RP-HPLC [6,7] methods so far developed for the estimation of Tucatinib were given in Table 1.
Table 1: Review of analytical methods.
The authors have briefly reviewed the analytical methods for the estimation of Relugolix in pharmaceutical dosage forms as well as biological fluids.
Copyright: © 2024 Mukthinuthalapati Mathrusri Annapurna and Pinninti Pradeep. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.